Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: Implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide

Haematologica

Volumn 96, Issue 2, 2011, Pages 319-322

  Göhring, Gudrun ^a   Giagounidis, Aristoteles ^b   Büsche, Guntram ^a   Hofmann, Winfried ^a   Kreipe, Hans Heinrich ^a   Fenaux, Pierre ^c   Hellström Lindberg, Eva ^d   Schlegelberger, Brigitte ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Johannes Hospital   (Germany)

^c AVICENNE HOSPITAL   (France)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Banding analysis; Cytogenetics; Del(5q); FISH; Follow up; Karyotyping; Therapy control

Indexed keywords

LENALIDOMIDE;

ANEMIA; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; INTERPHASE; KARYOTYPING; MAJOR CLINICAL STUDY; METAPHASE; MONOSOMY; MYELODYSPLASTIC SYNDROME; REMISSION; RISK FACTOR; SENSITIVITY ANALYSIS; TRISOMY; Y CHROMOSOME;

ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL RATE; THALIDOMIDE;

EID: 79551627899     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026658     Document Type: Article

References (24)

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds). IARC, Lyon 2008.
2. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004; 18(1):113-9.
3. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14):1456-65.
4. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10.
5. Göhring G, Giagounidis A, Büsche G, Kreipe H, Zimmermann M, Hellström-Lindberg E, et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010; 89(4):365-74.
6. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J, et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer. 2007;46(5):494-9.
7. Pitchford CW, Hettinga AC, Reichard KK. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. Am J Clin Pathol. 2010; 133(2):260-4.
8. Slovak ML, Dewald GW. International Working Group on MDS cytogenetics: October 2007 meeting report. Leuk Res. 2008;32(9):1329-32.
9. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
10. Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica. 2008;93(7): 1001-8.
11. Göhring G, Hanke C, Kratz C, Kontny U, Steinemann D, Niemeyer C, et al. Fluorescence in situ hybridization using the subtelomeric 11q probe as a diagnostic tool for congenital thrombocytopenia. Ann Hematol. 2006;85(12):883-5.
12. ISCN (1995): Guidelines for cancer cytogenetics, supplement to an international system for human cytogenetic nomenclature. Mitelman F (Ed). S. Karger, Basel, Switzerland 1995.
13. Team RDC. R: A language and environment for statistical computing [Internet]. Vienna, Austria: 2009. Available from: http://www.R-project.org
14. Cherry AM, Brockman SR, Paternoster SF, icks GA, Neuberg D, Higgins RR, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res. 2003;27(12):1085-90.
15. Bernasconi P, Cavigliano PM, Boni M, Calatroni S, Klersy C, Giardini I, et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia. 2003;17(11):2107-12.
16. Beyer V, Castagné C, Mühlematter D, Parlier V, Gmür J, Hess U, et al. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: oncordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet. 2004;152(1):29-41.
17. Yilmaz Z, Sahin FI, Kizilkilic E, Karakus S, Boga C, Ozdogu H. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients. Clin Exp Med. 2005;5(2):55-9.
18. Olney HJ, Le Beau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res. 2007;31(4):427-34.
19. Ketterling RP, Wyatt WA, VanWier SA, Law M, Hodnefield JM, Hanson CA, et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. Leuk Res. 2002;26(3): 235-40.
20. Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti AM, Grasso R, et al. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with imatinib mesylate. J Exp Clin Cancer Res. 2004;23(2):295-9.
21. Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi C, Stacchini M, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood. 2009;114(24):4939-43.
22. Duell T, Poleck-Dehlin B, Schmid C, Wunderlich B, Ledderose G, Mittermuller J, et al. Clonal karyotype evolution involving ring chromosome 1 with myelodysplastic syndrome subtype RAEB-t progressing into acute leukemia. Acta Haematol. 2006; 116(2):131-6.
23. Wang H, Wang X, Xu X, Lin G. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet Cytogenet. 2010;196(2):159-66.
24. Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, et al. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci USA. 2007;104(21):8995- 9000.